Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience.
Fiche publication
Date publication
janvier 2024
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CORMIER Luc, Dr LADOIRE Sylvain, Dr DESMOULINS Isabelle, Dr ZANETTA Sylvie, Dr MAYEUR Didier
Tous les auteurs :
Baude J, Niogret J, Jacob P, Bardet F, Desmoulins I, Zanetta S, Kaderbhai C, Galland L, Mayeur D, Delattre B, Cormier L, Ladoire S
Lien Pubmed
Résumé
Chemotherapy using carboplatin and etoposide (CE) is frequently pragmatically proposed to treat metastatic prostate cancer (mPC), both primary small-cell neuroendocrine (PSC-NE) carcinoma and adenocarcinoma with or without neuroendocrine (NE) marker elevation. However, the real benefit of CE is poorly reported in the recent therapeutic context.
Mots clés
NSE, PSA, anaplastic, carboplatin, chromogranin, etoposide, neuroendocrine, prostate cancer, survival
Référence
Cancers (Basel). 2024 01 9;16(2):